Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Inhibidor integrase")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 448

  • Page / 18
Export

Selection :

  • and

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor DolutegravirSONG, Ivy; BORLAND, Julie; SHUGUANG CHEN et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 3, pp 1627-1629, issn 0066-4804, 3 p.Article

Quinoline-based HIV Integrasc Inhibitors : The Development of Novel Inhibitors for the Treatment of HIV InfectionMUSIOL, Robert.Current pharmaceutical design (Print). 2013, Vol 19, Num 10, pp 1835-1849, issn 1381-6128, 15 p.Article

Integrase Inhibitors Effective against Human T-Cell Leukemia Virus Type 1MUHAMMAD ESA SEEGULAML; RATNER, Lee.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 5, pp 2011-2017, issn 0066-4804, 7 p.Article

Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimenROQUEBERT, Benedicte; BLUM, Laurent; COLLIN, Gilles et al.AIDS (London). 2008, Vol 22, Num 15, pp 2045-2046, issn 0269-9370, 2 p.Article

Exacerbation of depression associated with starting raltegravir : a report of four casesHARRIS, Marianne; LARSEN, Gerene; MONTANER, Julio S. G et al.AIDS (London). 2008, Vol 22, Num 14, pp 1890-1892, issn 0269-9370, 3 p.Article

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor DolutegravirCOTTRELL, Mackenzie L; HADZIC, Tanja; KASHUBA, Angela D. M et al.Clinical pharmacokinetics. 2013, Vol 52, Num 11, pp 981-994, issn 0312-5963, 14 p.Article

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor ElvitegravirRAMANATHAN, Srinivasan; MATHIAS, Anita A; GERMAN, Polina et al.Clinical pharmacokinetics. 2011, Vol 50, Num 4, pp 229-244, issn 0312-5963, 16 p.Article

Raltegravir-induced cerebellar ataxiaREISS, Kim A; BAILEY, Justin R; PHAM, Paul A et al.AIDS (London). 2010, Vol 24, Num 17, issn 0269-9370, p. 2757Article

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744FORD, Susan L; GOULD, Elizabeth; SHUGUANG CHEN et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 11, pp 5472-5477, issn 0066-4804, 6 p.Article

Divalent Metals and pH Alter Raltegravir Disposition In VitroMOSS, Darren M; SICCARDI, Marco; MURPHY, Matthew et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 3020-3026, issn 0066-4804, 7 p.Article

Update on Raltegravir and the Development of New Integrase Strand Transfer InhibitorsLEE SHAMROE, Caitlin; BOOKSTAVER, Paul Brandon; ROKAS, Kristina E. E et al.Southern medical journal (Birmingham, Ala. Print). 2012, Vol 105, Num 7, pp 370-378, issn 0038-4348, 9 p.Article

Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tubeTAEGTMEYER, Anne B; MÜLLER, Veronique; KOVARI, Helen et al.AIDS (London). 2011, Vol 25, Num 10, pp 1339-1341, issn 0269-9370, 3 p.Article

Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing RaltegravirCANDUCCI, Filippo; CERESOLA, Elisa R; BOERI, Enzo et al.The Journal of infectious diseases. 2011, Vol 204, Num 11, pp 1811-1815, issn 0022-1899, 5 p.Article

Raltegravir Penetration in Seminal Plasma of Healthy VolunteersCALCAGNO, Andrea; BONORA, Stefano; D'AVOLIO, Antonio et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 6, pp 2744-2745, issn 0066-4804, 2 p.Article

In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase InhibitorKOBAYASHI, Masanori; YOSHINAGA, Tomokazu; KAWAUCHI-MIKI, Shinobu et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 2, pp 813-821, issn 0066-4804, 9 p.Article

Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy VolunteersLINGZHI WANG; GAIK HONG SOON; SENG, Kok-Yong et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 9, pp 4090-4095, issn 0066-4804, 6 p.Article

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy VolunteersMIN, Sherene; SONG, Ivy; BORLAND, Julie et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 1, pp 254-258, issn 0066-4804, 5 p.Article

Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)SHIMURA, Kazuya; KODAMA, Eiichi; KANO, Mitsuki et al.Journal of virology. 2008, Vol 82, Num 2, pp 764-774, issn 0022-538X, 11 p.Article

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In VitroMALET, Isabelle; DELELIS, Olivier; KATLAMA, Christine et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 4, pp 1351-1358, issn 0066-4804, 8 p.Article

Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compoundsBONA, Roberta; ANDREOTTI, Mauro; COSTI, Roberta et al.Antimicrobial agents and chemotherapy. 2006, Vol 50, Num 10, pp 3407-3417, issn 0066-4804, 11 p.Article

Characterization of Binding of Raltegravir to Plasma ProteinsBARAU, Caroline; FURLAN, Valérie; YAZDANPANAH, Yazdan et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 10, pp 5147-5150, issn 0066-4804, 4 p.Article

Severe rhabdomyolysis associated with raltegravir useZEMBOWER, Teresa R; GERZENSHTEIN, Lana; COLEMAN, Karen et al.AIDS (London). 2008, Vol 22, Num 11, pp 1382-1384, issn 0269-9370, 3 p.Article

Assessment of the pharmacokinetics of co-administered maraviroc and raltegravirANDREWS, Emma; GLUE, Paul; JUANZHI FANG et al.British journal of clinical pharmacology. 2010, Vol 69, Num 1, pp 51-57, issn 0306-5251, 7 p.Article

Effect of Prednisone on the Pharmacokinetics of the Integrase Inhibitor DolutegravirSONG, Ivy H; BORLAND, Julie; SHUGUANG CHEN et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 9, pp 4394-4397, issn 0066-4804, 4 p.Article

Next-Generation Integrase Inhibitors: Where to After Raltegravir?KARMON, Sharon L.Drugs (Basel). 2013, Vol 73, Num 3, pp 213-228, issn 0012-6667, 16 p.Article

  • Page / 18